Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,012.82 USD

1,012.82
1,071,783

-1.77 (-0.17%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ekta Bagri headshot

Antibody Treatments for COVD-19 Face Challenges in the U.S.

by Ekta Bagri

With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.

Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids

by Zacks Equity Research

Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.

Bryan Hayes headshot

BioPharma Giants Print Fresh All-Time Highs

by Bryan Hayes

The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.

Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.

VIR Stock Down on Another Setback for COVID-19 Antibody

by Zacks Equity Research

VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.

Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Regeneron (REGN) Stock Moves -0.99%: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $691.47 in the latest trading session, marking a -0.99% move from the prior day.

Roche (RHHBY) Actemra Application Receives Priority Review

by Zacks Equity Research

Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accepted and granted Priority Review in the United States.

Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA

by Zacks Equity Research

The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.

Novartis (NVS) Beovu Gets Label Expansion for DME in EU

by Zacks Equity Research

Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.

Regeneron (REGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $698.43, moving +0.73% from the previous trading session.

AstraZeneca (AZN) Gets EU Nod for COVID-19 Antibody Cocktail

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.

Regeneron (REGN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Regeneron (REGN) closed at $693.20, marking a +1.06% move from the previous day.

Regeneron (REGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $665.93, moving +1.45% from the previous trading session.

Regeneron (REGN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $642.58, moving +1.94% from the previous trading session.

Intellia (NTLA) Depreciates 27% Over a Month: Here's Why

by Zacks Equity Research

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

The Zacks Analyst Blog Highlights Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences

by Zacks Equity Research

Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.

Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML

by Zacks Equity Research

Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.

Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates

by Zacks Equity Research

Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.

BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study

by Zacks Equity Research

BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.

Ekta Bagri headshot

WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients

by Ekta Bagri

Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.

SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets

by Zacks Equity Research

Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.

Kodiak (KOD) Down More Than 80% in Past 3 Months: Here's Why

by Zacks Equity Research

Kodiak Sciences (KOD) is developing its lead candidate, KSI-301, for treating various retinal vascular diseases. The recent setback for KSI-301 has hurt the stock.

Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.

Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.